Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1/ENGOT-OV30 trial.

We noted a marked trend toward increased abundance of M‐MDSCs following progression (Fig. 3G ); however, this did not reach statistical significance ( P adj = 0.0537). 3.6 PD‐L1 expression is upregulated on T cells during oleclumab/durvalumab treatment We subsequently performed differential analyses of cell state marker expression levels to investigate inter‐group differences and longitudinal changes in the activation, exhaustion, or terminal differentiation of leukocytes, as well as in the activity of signaling pathways potentially influenced by inhibition of adenosinergic signaling [ 30 ].

also in 135 other papers

We also observed a strong trend toward an increased relative abundance of circulating M‐MDSCs at progression.

also in 1,406 other papers

3G ); however, this did not reach statistical significance ( P adj = 0.0537). 3.6 PD‐L1 expression is upregulated on T cells during oleclumab/durvalumab treatment We subsequently performed differential analyses of cell state marker expression levels to investigate inter‐group differences and longitudinal changes in the activation, exhaustion, or terminal differentiation of leukocytes, as well as in the activity of signaling pathways potentially influenced by inhibition of adenosinergic signaling [ 30 ].

also in 39,124 other papers